guidelines.To compare the predictive value of the current AJCC stage grouping for renal cell carcinoma (RCC) to our modifications.
INTRODUCTION AND OBJECTIVES: Pathological upstaged pT3a for Renal Cell Carcinoma (RCC) may have a wide variance in outcomes. We sought to redefine and reclassify pT3a RCC. We investigated recurrence and survival outcomes in pT3a disease and aimed to better categorize this cohort for improvement on current TMN staging.
METHODS: Multicenter retrospective analysis of patients with cT1-3aN0M0 RCC who underwent radical or partial nephrectomy. After comparison of outcomes between pT1, pT2 and pT3a, patients were substratified within the pT3a category based on presenting clinical stage. Survival outcomes in T3a RCC were compared based on initial presenting clinical T stage. Comparison was drawn between pT1, pT2 and the subdivided pT3a group (cT1/pT3a, cT2/pT3a, and cT3a/pT3a). Primary outcome was recurrence free survival (RFS). Secondary outcome was overall survival (OS). Multivariable (MVA) and Kaplan-Meier (KM) analysis were conducted to elucidate risk factors and outcomes. RESULTS: We analyzed 2573 patients (1223 RN/1350 PN, median follow up 50.8 months). On MVA, higher clinical stage was a proportionally increasing predictor for risk of upstaging [compared to cT1a, OR of upstaging for cT1b, cT2a and cT2b was 2.6, 6.5, and 14.1, p<0.001] and recurrence [compared to cT1a upstaged to pT3a, HR for cT1b, cT2a, and cT2b upstaged to pT3a was 1.04 (p[0.912), 2.59 (p[0.008), and 2.7 (p[0.009)] . With regards to RFS, when pT3a was subdivided based on presenting clinical stage, significant differences in RFS emerged which aligned differently. Compared to 5 year RFS of pT1 (94.4%), cT1/pT3a aligned with pT2 (76.6% and 81.2%, p[0.346) while cT2/pT3a aligned with cT3a/pT3a 47.4% and 44.0%, p[0.815). With regards to OS, a similar alignment was noted for 5 year INTRODUCTION AND OBJECTIVES: Criteria for staging of T1 renal tumors into T1a ( 4cm) and T1b (4cm< and 7cm) have remained unchanged since 1997. Advancements in tumor biology have led to great understanding of the heterogeneous potential of T1 renal tumors. We hypothesized that a three-tier classification may more rationally risk stratify T1 renal masses than the current T1a/T1b system. METHODS: Multicenter (UCSD, Emory, Fox Chase Cancer Center, Ospadele San Raffaele) retrospective analysis of patients with cT1 renal cell carcinoma (RCC) undergoing partial or radical nephrectomy. Patients were stratified by tumor size into three groups cT1a ( 2cm, very low risk), cT1b (2cm< and 5cm, low risk), and cT1c (5cm< and 7cm, intermediate risk). Primary outcome was recurrencefree survival (RFS). Secondary outcome was overall survival (OS). Multivariable Cox Regression analysis (MVA) and Kaplan-Meier analyses (KMA) were utilized for outcomes.
RESULTS: 4710 patients were stratified into proposed T1 groups (T1a [856, T1b[2909, T1c[945; median follow-up 39 months). Mean age increased with tumor size (T1a 57.4 yrs, T1b 60.1 yrs, T1c 70.0 yrs, p<0.001) as did total RENAL scores (T1a 6.5, T1b 7.6, T1c 9.0, p<0.001). For cT1a, cT1b and cT1c tumors, KMA revealed 5 year RFS of 95.7%, 90.8%, and 80.8%, (p<0.001; Figure 1a ) and 5 year OS of 89.3%, 85.5%, and 73.3% (p[<0.001, Figure 1b) CONCLUSIONS: Subclassification of cT1 RCC into three clinical stage categories corresponds to distinctive tumor groups whose biological potential varies significantly. Division into three distinct categories may enhance risk stratification, refine preoperative counseling, and augment postoperative follow-up protocols by delineating a very low risk and intermediate risk subset of renal tumors. gene) are managed at our institution based on genotype. Active surveillance (AS) until 3 cm is employed for VHL, FLCN, and METaltered tumors, while immediate surgical resection is used for FH and SDHB tumors. BAP1-associated tumors are a more recently described entity that is associated with high grade, high stage RCC, and while we do not routinely perform AS for these lesions, some patients have undergone a period of AS prior to being diagnosed with BAP1 alterations. We sought to characterize the growth of genetically-defined tumors during AS.
Source of
METHODS: Patients managed on prospective National Cancer Institute Institutional Review-approved protocols with germline alterations in VHL, FLCN, MET, and BAP1 and multiple cross-
